scholarly article | Q13442814 |
P356 | DOI | 10.1373/CLINCHEM.2011.174359 |
P698 | PubMed publication ID | 22110019 |
P50 | author | Sabina A Murphy | Q114308442 |
P2093 | author name string | Christopher P Cannon | |
David A Morrow | |||
Eugene Braunwald | |||
Petr Jarolim | |||
E Wilson Grandin | |||
Lea Ritterova | |||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | acute coronary syndrome | Q266018 |
P304 | page(s) | 267-273 | |
P577 | publication date | 2011-11-22 | |
P1433 | published in | Clinical Chemistry | Q849687 |
P1476 | title | Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22 | |
P478 | volume | 58 |
Q34997796 | Assessment of the Relationship between Galectin-3 and Ejection Fraction and Functional Capacity in the Patients with Compensated Systolic Heart Failure |
Q64233589 | Biomarkers in Routine Heart Failure Clinical Care |
Q26991726 | Cardiac biomarkers: new tools for heart failure management |
Q36877555 | Circulating Galectin-3 Is Associated With Cardiometabolic Disease in the Community |
Q38687046 | Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure |
Q34102031 | Comparison the prognostic value of galectin-3 and serum markers of cardiac extracellular matrix turnover in patients with chronic systolic heart failure |
Q36917873 | Galectin 3 complements BNP in risk stratification in acute heart failure. |
Q35931701 | Galectin-3 Binding Protein Secreted by Breast Cancer Cells Inhibits Monocyte-Derived Fibrocyte Differentiation |
Q90152813 | Galectin-3 Is a Potential Mediator for Atherosclerosis |
Q49400435 | Galectin-3 and the incidence of abdominal aortic aneurysm: the atherosclerosis risk in communities (ARIC) study |
Q33577541 | Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study |
Q90690500 | Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure |
Q36439679 | Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community |
Q48159180 | Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z. |
Q90677157 | Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes |
Q93099741 | Mechanisms of cardiac collagen deposition in experimental models and human disease |
Q39017333 | Myocardial and Serum Galectin-3 Expression Dynamics Marks Post-Myocardial Infarction Cardiac Remodelling |
Q38471023 | Prognostic value of galectin-3 in patients with heart failure |
Q37580709 | Serial galectin-3 and future cardiovascular disease in the general population |
Q38154222 | The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers |
Q38761942 | The emerging role of galectins in cardiovascular disease |
Q92474328 | The relationship between galectin-3 levels and fragmented QRS (fQRS) in patients with heart failure with reduced left ventricular ejection fraction |
Search more.